美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

291.93

-2.6200-0.89%

盘后：291.930.00000.00%16:20 EDT

成交量：32.00万

成交额：9,306.55万

市值：346.38亿

市盈率：-78.83

高：292.34

开：288.94

低：287.41

收：294.55

数据加载中...

总览公司新闻公告

7月10日百济神州宣布欧盟委员会（EC）已批准百泽安（替雷利珠单抗）联合吉西他滨和顺铂用于不适合根治性手术或放疗的转移或

百济神州7月9日成交额为9172.04万美元

港股早评：三大指数低开科技股多数下跌宁德时代开涨2.6%再创新高

百奥赛图与百济神州达成抗体分子许可协议，加速创新药物开发

美国商业资讯

百济神州美股涨逾3%

每日经济新闻

百济神州美股涨逾3%一季度中国创新药海外授权总额再创新高。

【美股异动 | 百济神州(ONC.US)涨逾3% 一季度中国创新药海外授权总额再创新高】智通财经APP获悉，周三，百济神

美股异动 | 百济神州(ONC.US)涨逾3% 一季度中国创新药海外授权总额再创新高

百济神州7月8日成交额为6492.56万美元

又有2款创新药拟纳入优先审评，来自百济神州、艾力斯

刚刚，原百济神州大中华区CFO去向曝光！

一款国产抗癌药，“少卖”570亿

中国企业家杂志

百济神州 DLL3/CD3 双抗拟纳入优先审评

Insight数据库

研报掘金丨天风证券：维持百济神州“买入”评级，CDK4抑制剂展现出优异早期疗效信号

百济神州：CDK4抑制剂展现出优异早期疗效信号后续将进入注册临床研究阶段

天风证券股份有...

百济神州7月7日成交额为7745.23万美元

中国医药行业：理性看待创新药估值寻找优秀公司的买点

创新药大牛市继续，最受益也是中国最强的创新药龙头，高瓴资本重仓公司！

2025年医药市场格局重塑：创新药企突围与投资新机遇分析及数据解读

剔除CXO，创新药指数迎“提纯”！

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":291.93,"timestamp":1753128000000,"preClose":294.55,"halted":0,"volume":319984,"hourTrading":{"tag":"盘后","latestPrice":291.93,"preClose":291.93,"latestTime":"16:20 EDT","volume":3090,"amount":902085.1755000001,"timestamp":1753129200344},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"盘后交易","change":-2.62,"latestTime":"07-21 17:18:39 EDT","open":288.94,"high":292.34,"low":287.405,"amount":93065496.22554,"amplitude":0.016754,"askPrice":293.2,"askSize":100,"bidPrice":287,"bidSize":21,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1753142400000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":294.55,"preHourTrading":{"tag":"盘前","latestPrice":288.67,"preClose":294.55,"latestTime":"09:27 EDT","volume":12657,"amount":3725690.72484,"timestamp":1753104470064},"postHourTrading":{"tag":"盘后","latestPrice":291.93,"preClose":291.93,"latestTime":"16:20 EDT","volume":3090,"amount":902085.1755000001,"timestamp":1753129200344},"volumeRatio":0.53904,"impliedVol":0.4314,"impliedVolPercentile":0.5294},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.53904,"shares":118650120,"dividePrice":0,"high":292.34,"amplitude":0.016754,"preClose":294.55,"low":287.405,"week52Low":152.81,"pbRate":"9.90","psRate":"8.29","week52High":300,"institutionHeld":0,"latestPrice":291.93,"committee":-0.652893,"eps":-3.70325,"divideRate":0,"volume":319984,"delay":0,"ttmEps":-3.70325,"open":288.94,"prevYearClose":184.71,"prevWeekClose":294.55,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":252.14,"twentyDayClose":247.08,"sixtyDayClose":249.13,"earningDate":1754409600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550649333","title":"7月10日百济神州宣布欧盟委员会（EC）已批准百泽安（替雷利珠单抗）联合吉西他滨和顺铂用于不适合根治性手术或放疗的转移或","url":"https://stock-news.laohu8.com/highlight/detail?id=2550649333","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550649333?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 18:18","pubTimestamp":1752142682,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06160","BK1161","BK4526","LU2328871848.SGD","688235","ONC","LU0588546209.SGD","BK4201","EC","LU0307460666.USD","BK1500","LU1969619763.USD","BK4139","BK1588","BK1583","BK0239"],"gpt_icon":0},{"id":"2550694920","title":"百济神州7月9日成交额为9172.04万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550694920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550694920?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 12:37","pubTimestamp":1752122269,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，百济神州成交额为9172.04万美元，成交额较昨日增加41.27%，当日成交量为36.11万股。百济神州于2025年7月9日涨4.59%，报255.69美元，该股过去5个交易日涨4.3%，年初至今涨38.43%，过去60日涨22.74%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2550667221","title":"港股早评：三大指数低开 科技股多数下跌 宁德时代开涨2.6%再创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2550667221","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550667221?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 09:27","pubTimestamp":1752110862,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09618","HXXD.SI","03690","MIUmain","ALBmain","JKS","300750","HHImain","159871","HSCEI","03750","HSTECH","02097","METmain","YANG","HSImain","HSI","159992","BABA","XIACY","BIDU","01877","06160","TTTN","02833","688235","000819.SH","JD","HMTD.SI","07226","06978","KSTmain","01024","NTES","688180","03086","ONC","09999","161726","02555","89618","06683","MHImain","01810","MPNGY","81024","399441","165316","02382"],"gpt_icon":0},{"id":"2550661203","title":"百奥赛图与百济神州达成抗体分子许可协议，加速创新药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2550661203","media":"美国商业资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550661203?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 00:00","pubTimestamp":1752076800,"startTime":"0","endTime":"0","summary":"-- 百奥赛图，一家创新技术驱动新药研发的国际性生物技术公司，今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款，百济神州将向百奥赛图支付首付款。关于百济神州百济神州是一家注册地位于瑞士的全球肿瘤治疗创新公司，专注于为全世界的癌症患者研发创新抗肿瘤药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","688235","BK1500","BK1574","LU0588546209.SGD","LU0307460666.USD","ONC","BK1583","LU2328871848.SGD","BK1161","06160","06978","LU1969619763.USD","02315"],"gpt_icon":0},{"id":"2550659831","title":"百济神州美股涨逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550659831","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550659831?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 22:06","pubTimestamp":1752069960,"startTime":"0","endTime":"0","summary":"每经AI快讯，7月9日，百济神州美股涨逾3%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688235","06160","BK1583","LU2328871848.SGD","BK4139","LU0588546209.SGD","LU0307460666.USD","BK1588","ONC","BK1161","LU1969619763.USD","BK4526","BK1500"],"gpt_icon":0},{"id":"2550318655","title":"百济神州美股涨逾3%一季度中国创新药海外授权总额再创新高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550318655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550318655?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 22:04","pubTimestamp":1752069866,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1161","BK4526","159992","BK1574","06978","06160","BK1588","BK4139","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","688235","BK0239","LU0588546209.SGD","BK1500","ONC"],"gpt_icon":0},{"id":"2550655816","title":"【美股异动 | 百济神州(ONC.US)涨逾3% 一季度中国创新药海外授权总额再创新高】智通财经APP获悉，周三，百济神","url":"https://stock-news.laohu8.com/highlight/detail?id=2550655816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550655816?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 21:59","pubTimestamp":1752069554,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1588","01276","600276","BK0196","LU2495084118.USD","BK1574","BK0060","BK0183","BK4526","BK1583","LU2488822045.USD","LU0588546209.SGD","LU1328615791.USD","BK1161","ONC","LU2148510915.USD","BK1191","BK1500","LU1997244956.HKD","LU1655091616.SGD","03933","LU1064130708.USD","LU0307460666.USD","BK4139","BK0188","LU2328871848.SGD","06160","LU0405327148.USD","LU0405327494.USD","BK0012","BK0239","688235","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","159992","BK0028","LU1997245177.USD","06978"],"gpt_icon":0},{"id":"2550165585","title":"美股异动 | 百济神州(ONC.US)涨逾3% 一季度中国创新药海外授权总额再创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2550165585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550165585?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 21:59","pubTimestamp":1752069554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百济神州涨逾3%，报252.97美元。尤其，中国创新药License-out交易额激增，2024年海外授权首付款31.6亿美元，交易总额511亿美元，联邦制药、恒瑞医药等多笔大额授权刷新纪录，全球BD交易占比升至30%。2025年一季度，海外授权总额再创455亿美元纪录，并且已经接近2024年全年水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","BK1583","LU0307460666.USD","06978","LU1969619763.USD","06160","BK0239","BK1161","BK4139","BK1588","BK4526","688235","LU2328871848.SGD","ONC","159992","BK1574","LU0588546209.SGD"],"gpt_icon":0},{"id":"2550504187","title":"百济神州7月8日成交额为6492.56万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550504187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550504187?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 12:35","pubTimestamp":1752035720,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日，百济神州成交额为6492.56万美元，成交额较昨日减少16.17%，当日成交量为26.57万股。百济神州于2025年7月8日涨1.44%，报244.47美元，该股过去5个交易日涨0.99%，年初至今涨32.35%，过去60日涨18.49%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2550276505","title":"又有2款创新药拟纳入优先审评，来自百济神州、艾力斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2550276505","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550276505?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 10:44","pubTimestamp":1752029048,"startTime":"0","endTime":"0","summary":"此次在中国拟纳入优先审评，将加速其在中国的上市进程，为中国患者带来福音。优先审评是 CDE 推出的加速药物获批上市的重要政策之一。此次百济神州的注射用塔拉妥单抗和艾力斯的甲磺酸伏美替尼片拟纳入优先审评，将有助于它们更快地进入市场，为癌症患者带来新的生机，推动我国肿瘤治疗领域的进一步发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709104646953b9c40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709104646953b9c40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","688578","BK4526","06160","688235"],"gpt_icon":0},{"id":"2550284503","title":"刚刚，原百济神州大中华区CFO去向曝光！","url":"https://stock-news.laohu8.com/highlight/detail?id=2550284503","media":"CFO职业圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550284503?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 10:14","pubTimestamp":1752027296,"startTime":"0","endTime":"0","summary":"时隔4个月，他的新职位终于公布。详见《重磅！百济神州大中华区CFO离职》。加入亚盛医药之前，黄智先生担任百济神州大中华区和亚太区首席财务官、全球技术运营和全球商业财务负责人。在百济任职期间，他通过完整的全面预算管理及合理的全球布局资源优化，持续改善公司财务状况。据Veet Misra的领英资料，其工作经历详细如下：温馨提示关注并星标“CFO职业圈”，不错过每一篇新推送！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2550571442","title":"一款国产抗癌药，“少卖”570亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2550571442","media":"中国企业家杂志","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550571442?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 08:00","pubTimestamp":1752019249,"startTime":"0","endTime":"0","summary":"6月2日，美国药企BMS与德国药企BNT宣布达成战略合作：双方将共同开发双抗药物BNT327，交易总金额高达90亿美元。在许多投资者看来，才一年多时间，这款药就溢价了80亿美元量级，普米斯“低价卖青苗”，被中间商赚了差价。最具代表性的企业是再鼎医药，一度通过密集引进14款药物，先后在美国、中国香港上市，市值曾突破千亿港元，股价超越腾讯，成为“最贵港股”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709080335a43ee493&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709080335a43ee493&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","02696","01276","BK4585","LEGN","600276","688331","09995","BK4505","02162","BK4139","ZLAB","06160","688321","01530","688235","ONC","09688","BK4588","06998"],"gpt_icon":0},{"id":"2549510933","title":"百济神州 DLL3/CD3 双抗拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2549510933","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549510933?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 17:11","pubTimestamp":1751965869,"startTime":"0","endTime":"0","summary":"7 月 8 日，CDE 官网显示，百济神州申报的注射用塔拉妥单抗拟纳入优先审评，用于既往接受过至少 2 线治疗失败的广泛期小细胞肺癌成人患者的治疗。2025 年 5 月，百济神州宣布，与安进公司在中国联合开展的注射用塔拉妥单抗2 期临床研究 DeLLphi-307 已取得积极结果。基于 DeLLphi-301、DeLLphi-304 和 DeLLphi-307 研究所获得的积极结果，塔拉妥单抗有望为中国 SCLC 患者的二线、三线及后线治疗提供新的用药选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1500","BK1588","LU0588546209.SGD","LU0307460666.USD","BK1161","06160","688235","ONC","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2549150765","title":"研报掘金丨天风证券：维持百济神州“买入”评级，CDK4抑制剂展现出优异早期疗效信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2549150765","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549150765?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 16:00","pubTimestamp":1751961645,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4225","BK4203","688235","BK4139","BK1500","BGB","HR","BK4581","LU1969619763.USD","BK0276","GLP","06160","LU2328871848.SGD","BK1588","BK4561","BK4585","601162","BK4526","ONC","BK1583","BK4590","LU0307460666.USD","BK4588","BK4144","BK1161","BK0239","ET","BK4190","LU0588546209.SGD","BC"],"gpt_icon":0},{"id":"2549515128","title":"百济神州：CDK4抑制剂展现出优异早期疗效信号 后续将进入注册临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2549515128","media":"天风证券股份有...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549515128?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 15:52","pubTimestamp":1751961140,"startTime":"0","endTime":"0","summary":"百济神州的CDK4 抑制剂BGB-43395 进度处于前列，有望成为全球第二款进入注册临床阶段的CDK4 抑制剂根据公司指引，BGB-43395 预计在未来的 6-12 个月内进入注册临床阶段。CDK4 抑制剂BGB-43395 在多个体内外药效评估中均展现出BIC 潜力BGB-43395 相较现有CDK4/6 抑制剂具有更高选择性。百济神州的BGB-43395 体内药代动力学数据符合预期，药效学活性强效。CDK4 抑制剂BGB-43395 具有更优抑制效力。所以对同靶点药物，百济神州的CDK4i 来说，3 个月的中位随访时间还未到中位起效时间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708155225979e0bc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708155225979e0bc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2549599755","title":"百济神州7月7日成交额为7745.23万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549599755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549599755?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 12:29","pubTimestamp":1751948965,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，百济神州成交额为7745.23万美元，成交额较昨日增加82.68%，当日成交量为32.09万股。百济神州于2025年7月7日跌1.83%，报240.99美元，该股过去5个交易日跌0.09%，年初至今涨30.47%，过去60日涨15.08%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122927a43d2e69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122927a43d2e69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2549596030","title":"中国医药行业：理性看待创新药估值 寻找优秀公司的买点","url":"https://stock-news.laohu8.com/highlight/detail?id=2549596030","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549596030?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 00:00","pubTimestamp":1751904000,"startTime":"0","endTime":"0","summary":"中国创新药的研发实力具备全球竞争力，创新药出海趋势将长期持续。创新药商保目录即将落地，对行业短期影响有限，长期将打开创新药支付空间。7 月1 日，医保局发布了医保目录和商保创新药目录调整工作方案，预计将于10-11 月公布结果。商保创新药目录采用价格协商的形式，由商保专家、医保部门与药企进行价格协商。但商业健康保险赔付率较低，2023 年商业健康保险赔付额仅为3,848 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708120124a69c4119&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708120124a69c4119&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","01530","02273","BK1219","BK1161","02367","06699","ONC","BK1574","01801"],"gpt_icon":0},{"id":"2549831645","title":"创新药大牛市继续，最受益也是中国最强的创新药龙头，高瓴资本重仓公司！","url":"https://stock-news.laohu8.com/highlight/detail?id=2549831645","media":"萝卜投研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549831645?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 15:14","pubTimestamp":1751872499,"startTime":"0","endTime":"0","summary":"高瓴资本是百济神州的十大股东之一！经调整后，公司实现营业利润11.71亿元，净利润8.85亿元。公司总资产为421亿元，归属于上市公司股东的所有者权益为252亿元。继首季度盈利之后，6 月 26 日，百济神州举行了投资者研发日活动。HER2双抗泽尼达妥单抗于上个月在中国获批上市，直指HER2阳性实体瘤群体尚未满足的临床需求。其二为2025年创新药头部上市公司扭亏，2026年更多公司盈利。短期来看，2025年有望成为创新药企业收入集体放量的起点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707151714a43b367b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707151714a43b367b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2298322129.HKD","LU2360107325.USD","LU0724618433.USD","06160","IE00BZ199S13.USD","LU2357305700.SGD","LU0124384867.USD","LU1861219969.SGD","LU1861214812.USD","ON","BK4526","LU1978683503.SGD","BK4585","LU1861215975.USD","LU1854104046.USD","BK4139","BK4588","ONC","BK4141","LU0348723411.USD","LU1720051108.HKD","BK4512","IE00BD6J9T35.USD","LU1548497426.USD","LU1861220033.SGD","LU1720051017.SGD","LU1854103824.USD","BK4605"],"gpt_icon":0},{"id":"2549010653","title":"2025年医药市场格局重塑：创新药企突围与投资新机遇分析及数据解读","url":"https://stock-news.laohu8.com/highlight/detail?id=2549010653","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549010653?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 11:01","pubTimestamp":1751857263,"startTime":"0","endTime":"0","summary":"行业数据显示，全球BCL-2抑制剂市场将在2028年达到52亿美元规模，而乳腺癌靶向药物市场规模更将突破163亿美元，为创新药企提供结构性增长空间。2025年医药市场呈现出鲜明的结构性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707124736979c9a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707124736979c9a9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2495084118.USD","600276","159938","BK0239","BK0196","06160","ONC","162414","LU1997245094.SGD","LU2488822045.USD","LU2328871848.SGD","BK0183","LU1328615791.USD","159992","BK0028","LU1969619763.USD","LU1064130708.USD","LU1655091616.SGD","LU0405327148.USD","LU0405327494.USD","LU1997244956.HKD","01276","688235","LU1997245177.USD","BK0060","LU2148510915.USD","BK0188","LU1064131003.USD","BK0012"],"gpt_icon":0},{"id":"2549718305","title":"剔除CXO，创新药指数迎“提纯”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2549718305","media":"侃见财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549718305?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 10:44","pubTimestamp":1751856299,"startTime":"0","endTime":"0","summary":"在板块高歌猛进之际，6月30日，恒生指数公司宣布对恒生港股通创新药指数进行关键修订：明确剔除CXO企业，打造“纯度”100%的创新药指数。这次指数修订，将一次性剔除5家CXO企业、合计权重约20%，它们年初以来的涨幅均落后于指数整体表现。修订规则生效后，恒生港股通创新药指数将成为目前ETF跟踪的指数中首批“纯度”达100%的创新药指数。回测显示，指数经过“提纯”后表现将有全面的提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707104842a699ffa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707104842a699ffa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK4139","600276","CXO","BK4526","01801","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.18,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-18","current":-87.653233,"percent":0.003509,"low":-89.808695,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"high":-19.234246,"avg":-40.25011,"sd":18.414403,"marketCap":34392148550},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550}],"updateTime":1753111361211}}}